Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
All content for Evaluating Biopharma is the property of Evaluating Biopharma and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
Episode: 13 - Identifying Impurities In Gene Therapy With Santoshkumar Khatwani
Evaluating Biopharma
19 minutes
2 years ago
Episode: 13 - Identifying Impurities In Gene Therapy With Santoshkumar Khatwani
In this episode of Evaluating Biopharma, host Ben Locwin speaks with Santoshkumar Khatwani, Director – Analytical Development, Late-Stage CMC Analytical Team Lead at Sangamo Therapeutics, about impurities in gene therapy processes and the ways to identify them. Khatwani discusses how to determine if these impurities are from the product, the process, or the host cell. He also talks about using multiple different analytical methods to help understand how good your process is or isn’t, what to ...
Evaluating Biopharma
Are cell therapies the key to bridging the gap between discovery research and clinical trials? In the inaugural episode of the Bioprocessing Unfiltered podcast, Bo Wiinberg, chief business development officer at Novo Nordisk Foundation Cellerator, sat with Ran Zheng, CEO of Landmark Bio and shared his expert insight on the promise cell therapies hold for diseases with only treatments but no cures. Their conversation covers the challenges of navigating cell therapy programs through pre-clinica...
